Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|7|2|149-155

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.7, Iss.2, 2007-03, pp. : 149-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Host responses to herpes simplex virus and herpes simplex virus vectors

By Hukkanen Veijo   Paavilainen Henrik   Mattila Riikka K  

Future Virology, Vol. 5, Iss. 4, 2010-07 ,pp. : 493-512

Future Medicine

Access to resources Recommend Favorite

Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy

By  

Current Gene Therapy, Vol. 8, Iss. 3, 2008-06 ,pp. : 208-221

Bentham Science Publishers

Access to resources Recommend Favorite

Piroxicam inhibits herpes simplex virus type 1 infection in vitro

By  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 5, 2015-01 ,pp. : 331-336

Govi-Verlag

Access to resources Recommend Favorite

Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens

By  

Current Cancer Drug Targets, Vol. 18, Iss. 2, 2018-01 ,pp. : 162-170

Bentham Science Publishers

Access to resources Recommend Favorite

Herpes stromal keratitis: erosion of ocular immune privilege by herpes simplex virus

By Knickelbein Jared E   Buela Kristine-Ann   Hendricks Robert L  

Future Virology, Vol. 5, Iss. 6, 2010-11 ,pp. : 699-708

Future Medicine

Access to resources Recommend Favorite